Capricor Therapeutics (CAPR) Net Margin: 2011-2025
Historic Net Margin for Capricor Therapeutics (CAPR) over the last 13 years, with Sep 2025 value amounting to -364,548.09%.
- Capricor Therapeutics' Net Margin fell 36399288.00% to -364,548.09% in Q3 2025 from the same period last year, while for Sep 2025 it was -219.62%, marking a year-over-year decrease of 9893.00%. This contributed to the annual value of -100.90% for FY2024, which is 1214.00% down from last year.
- Latest data reveals that Capricor Therapeutics reported Net Margin of -364,548.09% as of Q3 2025, which was down 87.66% from -194,260.36% recorded in Q2 2025.
- Capricor Therapeutics' Net Margin's 5-year high stood at -6.86% during Q4 2023, with a 5-year trough of -364,548.09% in Q3 2025.
- In the last 3 years, Capricor Therapeutics' Net Margin had a median value of -224.07% in 2023 and averaged -56,032.11%.
- As far as peak fluctuations go, Capricor Therapeutics' Net Margin spiked by 2,201,675bps in 2021, and later slumped by 36,399,288bps in 2025.
- Quarterly analysis of 5 years shows Capricor Therapeutics' Net Margin stood at -3,515.08% in 2021, then spiked by 271,430bps to -800.77% in 2022, then surged by 79,391bps to -6.86% in 2023, then tumbled by 1,744bps to -24.29% in 2024, then plummeted by 36,399,288bps to -364,548.09% in 2025.
- Its Net Margin stands at -364,548.09% for Q3 2025, versus -194,260.36% for Q2 2025 and -24.29% for Q4 2024.